Overview

Probiodrug is a privately held biopharmaceutical company focused on the development of innovative small molecule drugs. The Company was founded in 1997 and has raised a total of $52 million in private equity. In addition, it has generated more than $50 million in revenues and is debt-free.
Probiodrug is pioneering an industrialized approach for making innovative targets pharmacologically accessible. Its core competence is the elucidation of the structure, biochemistry, and biology as well as the pathophysiology of regulatory peptides and enzymes modifying the activity of specific proteins and pathways.
Based on this expertise, the Company is developing inhibitors and ligands targeting key enzymes such as proteases and kinases. The most promising compounds are then developed by Probiodrug as drug candidates for the treatment of major diseases such as Alzheimer’s disease or chronic inflammatory disorders.
Probiodrug addresses major pharmaceutical markets such as Alzheimer’s disease, psoriasis, rheumatoid arthritis or cardiovascular diseases.
The Company aims to bring these compounds through preclinical and clinical development up to proof-of-concept trials to provide a strong basis for selectively out-licensing its drugs to the pharmaceutical industry or entering into co-development partnerships.
At present, Probiodrug leverages its expertise with novel targets, such as Glutaminyl Cyclase (QC) and Cyclin-Dependent Kinase 9 (CDK9), to develop drugs for the treatment of widespread diseases such as Alzheimer’s disease and chronic inflammation. In Alzheimer’s, Probiodrug is pioneering a treatment paradigm shift towards a new causal mechanism, providing considerable first mover advantage. In CDK 9 inhibition Probiodrug has a significant competitive advantage in having highly potent and selective CDK 9 inhibitors available, the so far bottleneck in this field.
Probiodrug is located at the Biocenter Halle, which is part of the Weinberg-Campus at the University of Halle (Saale), Germany, and has a subsidiary, Ingenium GmbH, in Martinsried/Munich.